Pacira Pharmaceuticals, Inc.

Overview

• Industrypharmaceutical industry¹
• HeadquartersParsippany-Troy Hills, United States¹
• Websitewww.pacira.com
• Legal formDelaware corporation¹
• LEI549300P56LERYBDHCF69²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 4260946²

See how the biggest companies compare on our leaderboards

Corporate structure

Pacira Pharmaceuticals, Inc. is part of a group headed by Pacira BioSciences, Inc.. 9 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Timeline

1. 2006Founded Founded¹

Calendar

Drug trials and FDA: coming up

1. Nov 2026Phase 2 trial readout expected Phase 2 trial of Enekinragene Inzadenovec (PCRX-201) in Osteoarthritis (OA) of the Knee: primary completion expected Nov 2026 (ClinicalTrials.gov NCT06884865).³
2. Dec 2026Phase 3 trial readout expected Phase 3 trial of ZILRETTA in Glenohumeral Osteoarthritis: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06269705).⁴

Drug trials and FDA: recently

1. Nov 9, 2023FDA approved a new use FDA approved an efficacy supplement for Exparel (bupivacaine), a new use or patient group (NDA 022496, supplement 44).⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Links

• Websitewww.pacira.com¹
• WikidataQ21874175